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BACKGROUND: In anovulatory women undergoing ovulation induction, addition of recombinant human LH
(rLH) to FSH treatment may promote the dominance of a leading follicle when administered in the late follicular
phase. The objective of this study was to find the optimal dose of rLH that can maintain the growth of a dominant
follicle, whilst causing atresia of secondary follicles. METHODS: Women with infertility due to anovulation and
over-responding to FSH treatment were randomized to receive, in addition to 37.5 IU recombinant human FSH
(rFSH), either placebo or different doses of rLH (6.8, 13.6, 30 or 60mg) daily for a maximum of 7 days. The
primary efficacy endpoint was the proportion of patients who had exactly one follicle $16 mm on hCG day.
RESULTS: Among 153 enrolled patients, the five treatment groups were similar in terms of baseline character-
istics. The proportion of patients with exactly one follicle $16 mm ranged from 13.3% in the placebo group to
32.1% in the 30mg rLH group (P 5 0.048). The pregnancy rate ranged from 10.3% in the 60mg group to 28.6%
in the 30mg rLH group. Adverse events were similar between groups. CONCLUSIONS: In patients over-respond-
ing to FSH during ovulation induction, doses of up to 30mg rLH/day appear to increase the proportion of patients
developing a single dominant follicle ($16 mm). Our data support the ‘LH ceiling’ concept whereby addition of
rLH is able to control development of the follicular cohort.
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Introduction
Ovarian follicular development in the late stage of folliculo-
genesis requires the combined actions of two gonadotrophins:
FSH and LH. The pivotal role of FSH for follicular recruit-
ment and growth has been well demonstrated. In clinical
practice, a minimal FSH requirement, defined as the ‘FSH
threshold’, must be surpassed to initiate follicular growth
(Brown, 1978; Scheele et al., 1993; Fauser and Van Heusden,
1997). This concept has been applied to the stimulation of
WHO group II anovulatory women through a stepwise
administration of FSH, the so-called ‘chronic-low-dose
step-up protocol’ (Seibel et al., 1984; Buvat et al., 1989;
Hamilton-Fairley et al., 1991).
However, although follicular growth can be induced by
FSH in the total absence of LH, there is also some evidence
that optimal follicular development requires a minimal
exposure to LH to ensure adequate estradiol (E2) production,
full oocyte maturity, follicular rupture and the ability for
granulosa cells to be luteinized in response to hCG (Couzinet
et al., 1988; Glasier et al., 1988; Shoham et al., 1991;
Balasch et al., 1995). As demonstrated in patients suffering
from severe deficiency in LH and FSH, daily injections of
low doses of recombinant human LH (rLH; 75 IU) are
required to ensure optimal follicular maturation (European
Recombinant Human LH Study Group, 1998).
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LH receptors appear on granulosa cells that have been
adequately stimulated by FSH and the developing follicle
becomes increasingly dependent on LH (Richards et al.,
1987). In the granulosa cells of the pre-ovulatory follicle,
aromatase is functionally coupled to the LH receptors such
that LH directly regulates follicular estrogen secretion
(Zeleznik and Hillier, 1984; Zeleznik, 2001). Consequently,
substitution of FSH by LH therapy in the late follicular phase
is able to maintain adequate steroidogenesis (Sullivan et al.,
1999) and even final stages of follicular maturation (Balasch
and Fábregues, 2003).
On the other hand, the concept of an ‘LH ceiling’ was
initially based upon clinical observations that follicles
exposed to inappropriately high concentrations of LH enter
atresia or become prematurely luteinized, and oocyte devel-
opment may be compromised (Howles et al., 1986; Chappel
and Howles, 1991; Jacobs, 1991). The dose dependence of
this LH effect was illustrated by studies in vitro: ‘low-dose’
treatment with LH serves generally to enhance steroidogen-
esis without inhibiting DNA synthesis, but ‘high-dose’ LH
causes enhanced synthesis of progesterone, suppression of
aromatase activity and inhibition of cell growth (Overes et al.,
1992; Yong et al., 1992). Thus, developing follicles appear
to have finite requirements for stimulation by LH, beyond
which normal development ceases.
Whereas each follicle has a threshold beyond which it
must be stimulated by FSH to initiate pre-ovulatory develop-
ment (Brown, 1978), it may also have a ‘ceiling’ within
which it should be stimulated by LH, above which normal
development is terminated (Hillier, 1993). During the second
half of the follicular phase, as plasma FSH concentrations
decline, the LH-dependent phase of pre-ovulatory follicular
development only proceeds normally if LH is present at con-
centrations beneath this ceiling value (Hillier, 2000). When
the ceiling is exceeded at the mid-cycle surge of LH, further
division of granulosa cells would cease as luteinization
proceeds (Hillier, 1994).
In this respect, the potential effect of LH administration in
controlling the number of developing follicles deserves clini-
cal investigation. Recently, Loumaye et al. (2003) provided
evidence that rLH alone can trigger follicular growth arrest
in WHO group I or II anovulatory patients. Therefore, rLH
may be of particular use in treatment regimens that aim to
achieve mono-ovulation for conception in vivo. However, the
optimal dose of rLH required to induce atresia of secondary
follicles is still not established.
The objective of this prospective, randomized, double-
blind, multicentre study was to evaluate the effects of four
different doses of rLH administered in the late follicular
phase and to establish the minimal effective dose required to
promote maturation and ovulation of a single follicle while
inducing atresia in secondary follicles.
Materials and methods
Patients
This study was conducted in WHO Group II anovulatory women
fulfilling the following criteria: (i) pre-menopausal women aged
between 18 and 39 years, wishing to conceive; (ii) infertility due to
ovulatory dysfunction as based on WHO group II criteria
[normogonadotropic oligo-ovulation or anovulation attested by low
(,10 nmol/l) progesterone value 20–25 days after spontaneous or
progestogen-induced menses and undergoing treatment for ovulation
induction; (iii) body mass index (BMI) between 18 and 35 kg/m2;
(iv) at least one tube patent and a normal uterine cavity, as docu-
mented by hysterosalpingography, laparoscopy or hysteroscopy
within the past 5 years; (v) male partner with semen quality compa-
tible with conception following natural intercourse or intrauterine
insemination.
Study design
The study was conducted according to Good Clinical Practice guide-
lines, and ethical committee approval was obtained to conduct the
study in all participating centres.
To be eligible, patients were to have been stimulated with urinary
FSH (uFSH) or recombinant FSH (rFSH) for ovulation induction
and have started FSH treatment within 5 days of spontaneous or
induced menstruation. The starting dose of FSH was chosen to
achieve follicular recruitment without exceeding a daily dose of
150 IU according to the BMI. Women were enrolled in the study if
they were experiencing an excessive follicular response to FSH
stimulation treatment attested by the presence on ultrasound of at
least three follicles 11–15 mm in diameter, but no follicles .15 mm
in diameter at any point during stimulation with FSH. Patients were
then randomized to receive rLH or placebo in combination with
37.5 IU of rFSH daily from the day of randomization (S1) until the
criteria for hCG administration were reached, or for a maximum of
7 days (S7). The treatment period could be interrupted before com-
pletion if obvious regression of all follicles was recorded or if the
patient was at risk of developing ovarian hyperstimulation syndrome
(OHSS). A single injection of hCG (5000 IU) was given within 36 h
of the last rLH or placebo/rFSH injection if monitoring by ultra-
sound showed a maximum of two follicles with a mean diameter
$16 mm and if the total follicular number and the serum E2 levels
were not indicative of OHSS risk.
Randomization and medications used
Either urinary FSH (Metrodinw or Metrodin HPw; Serono, Switzer-
land) or rFSH (Gonal Fw; Serono) were used for the initial part of
the ovarian stimulation cycle, prior to randomization. Doses of rLH
(Luverisw; Serono) were selected for each patient in a randomized
fashion, without any stratification per treatment group. Subcutaneous
administration of 37.5 IU rFSH in addition to the rLH or placebo
injection was performed in every case, whatever the amount of FSH
used during the stimulation period prior to randomization.
rLH/rFSH administration was started on the day of randomization
(S1), once eligibility had been confirmed and the patient had given
her informed consent for entry into the study. Patients were random-
ized to one of the following treatments, all administered daily by
subcutaneous injection: (i) placebo; (ii) 6.8mg (150 IU) rLH; (iii)
13.6mg (300 IU) rLH; (iv) 30mg (660 IU) rLH; (v) 60mg (1325 IU)
rLH. rLH or placebo treatment assigned to each patient was deter-
mined according to a computer-generated randomization list strati-
fied by centre. A single injection of 5000 IU hCG (Profasiw;
Serono) was given when the criteria for triggering ovulation were
met, as described above.
Monitoring
Monitoring was primarily performed by vaginal ultrasono-
graphy. The examinations were performed weekly prior to
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the administration of rLH/placebo and daily during the treatment
period. All follicles with a mean diameter (i.e. the mean of the two
longest perpendicular diameters) .10 mm were recorded according
to their size. Whenever possible, the individual growth over time of
each follicle with a diameter $11 mm was recorded.
Blood samples were taken for local E2 measurements during the
whole period and for retrospective analysis of E2, progesterone, LH
and inhibin A and B, prior to administration of rLH/placebo and on
a daily basis up to the day of hCG administration (or the last day of
gonadotrophin treatment if no hCG was administered). The luteal
phase was assessed and monitored by measuring progesterone serum
values between day 6 and day 8 post-hCG.
Hormone assays
All assays were performed at a central laboratory: LCG Bioscience
Clinical (Science Department, Bourn Hall Clinic, Bourn, Cam-
bridge, UK). Serum FSH and LH were measured using a validated,
commercially available immunoradiometric assay (IRMA) method
(MAIAClone; Serono). The limit of quantification for serum FSH
and LH was 1 IU/l. Serum E2, progesterone, inhibin A and inhibin B
were measured using validated commercially available immuno-
assays. Centralized immediate safety biochemistry and haematology
analyses were performed by Covance CLS (Covance Central
Laboratory Services SA, Switzerland, Australia and USA).
Study endpoints and sample size calculation
The primary efficacy endpoint of the study was the proportion of
patients who received hCG and who had exactly one follicle
$16 mm in diameter. The main secondary efficacy endpoints were:
(i) proportion of patients who received hCG according to the proto-
col criteria; (ii) mean number of pre-ovulatory follicles ($16 mm in
diameter) on the day of hCG; (iii) mean number of medium-sized
follicles (between 11 and 15 mm in diameter); (iv) difference
between the number of baseline follicles compared with the number
of pre-ovulatory follicles on the day of hCG; (v) longitudinal fol-
licular growth (where possible); (vi) frequency of ovulation (luteal
phase progesterone levels $25 nmol/l); (vii) clinical pregnancy rate
and outcome.
It was planned to enrol a total of 150 evaluable patients (30
patients per group). This number was based upon the results
obtained from previous studies carried out in the same patient popu-
lation, assuming 80% power and 5% significance level (two-sided)
for the proportion of patients/cycle with exactly one follicle
$16 mm in diameter.
Statistical methods
The statistical method used depended on the nature of the variable
analysed. As one of the main objectives of the study was to find the
minimal effective dose of rLH, the primary analysis carried out was
that of a dose relationship, with a linear modelling using treatment
received as a factor for comparison. A parametric model (logistic
regression) was computed in order to perform the dose relationship
and subsequent pairwise comparisons. Paired comparisons were car-
ried out between placebo and each of the doses of rLH and then
between each rLH dose and each of the subsequent dosing regimes.
All secondary endpoints were analysed using the same methods of
statistical analysis described above. Other statistical tests such as
analysis of variance, logistic regression, exact logistic regression,
Cochran–Mantel–Haenszel or Fisher’s exact test were used as
appropriate. Due to observed differences between treatment groups
in BMI and dose of FSH prior to randomization, the analysis of the
primary endpoint was adjusted for these parameters in order to
better evaluate treatment effect.
Results
Demographic characteristics
Twenty-two participating centres enrolled a total of 153
patients, all of whom were allocated to one of the treatment
groups (31 to placebo; 32 to 6.8mg rLH; 29 to 13.6mg rLH;
30 to 30mg rLH; 31 to 60mg rLH). Six were excluded from
the evaluable patient (per-protocol) analysis due to major
protocol deviations that may have had a clinically significant
impact on the assessment of the efficacy of the study drug.
The proportion of these patients was balanced between
groups (one each from the placebo and 13.6mg rLH groups,
and two each from the 30 and 60mg rLH groups).
The main demographic parameters of the 147 analysed
patients were statistically balanced between treatment groups
as regards past medical history, current medical condition,
associated infertility factors, obstetric history, and baseline
hormonal parameters. A total of 132 (89.8%) patients had
been previously stimulated with clomiphene citrate and/or
gonadotrophins (Table I). The proportion of previously
Table I. Demographic characteristics
Placebo 6.8mg rLH 13.6mg rLH 30mg rLH 60mg rLH Total
No. of patients 30 32 28 28 29 147
Age (years) 29.9 (3.6) 29.5 (4.8) 29.9 (3.7) 28.6 (3.7) 29.3 (4.4) 29.5 (4.1)
BMI (kg/m2) 26.4 (4.7) 24.3 (4.5) 24.5 (3.7) 25.0 (4.6) 25.8 (4.5) 25.2 (4.4)
Type of infertility
Primary 20 (66.7) 23 (71.9) 18 (64.3) 19 (67.9) 23 (79.3) 103 (70.1)
Secondary 10 (33.3) 9 (28.1) 10 (35.7) 9 (32.1) 5 (17.2) 43 (29.3)
Missing – – – – 1 (3.4) 1 (0.7)
Duration of infertility (years) 3.3 (3.0) 4.3 (3.4) 4.1 (4.1) 3.1 (1.8) 3.7 (2.7) 3.7 (3.1)
Duration of anovulation (years) 8.7 (7.0) 10.3 (8.2) 10.6 (6.9) 9.2 (6.5) 8.9 (7.0) 9.5 (7.1)
Infertility-associated factors (%)
Male factor infertility 6 (20.0) 7 (21.9) 5 (17.9) 3 (10.7) 5 (17.2) 26 (17.7)
Endometriosis 1 (3.3) – 2 (7.1) 2 (7.1) 1 (3.4) 6 (4.1)
One patent tube – 1 (3.1) – – – 1 (0.7)
Other 1 (3.3) – 1 (3.6) – – 2 (1.4)
Previous stimulation (%) 26 (86.7) 28 (87.5) 25 (89.3) 27 (96.4) 26 (89.7) 132 (89.8)
Values are mean (SD).
BMI ¼ body mass index; rLH ¼ recombinant human LH.
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stimulated cycles (mean of 3.2 clomiphene citrate and mean
of 2.0 gonadotrophin cycles) was also balanced between
treatment groups.
Ovarian stimulation with FSH prior to randomization
The duration of FSH treatment prior to randomization ranged
from 3 to 28 days, with a mean duration of 9.7 days. The
dose of FSH administered ranged from 200 to 3300 IU, with
a mean dose of 985 IU (Table II). Although not statistically
significant, some differences were observed between treat-
ment groups (P ¼ 0.28 and 0.22 respectively). At the time of
randomization, the number of follicles with a mean diameter
between 11 and 15 mm ranged from 3 to 15, with a mean of
5.1 follicles. No follicle .15 mm in diameter was seen on
the ultrasound of any of the patients, confirming that all
patients were eligible for study entry. These parameters were
considered by the statistical analysis to be balanced between
treatment groups.
Efficacy results
The efficacy data set included all randomized patients who
completed the scheduled rLH administration without major
deviation from the protocol (n ¼ 147). The mean duration of
treatment was 2.9 days, with a range from 1 to 7 days. Over-
all, the mean duration did not differ statistically between
treatment groups. Of the 147 patients who received rLH/pla-
cebo treatment, 94 (64%) received hCG according to the pro-
tocol. The other 53 (36%) patients withdrew before receiving
hCG and did not complete the study: 43 failed to meet the
protocol criteria for hCG administration (due to the risk of
multiple pregnancy), nine presented follicular regression and
one withdrew on her own decision. The proportion of
patients who discontinued was statistically balanced between
treatment groups.
The primary efficacy endpoint of the study was the pro-
portion of patients who received hCG and who had exactly
one follicle $16 mm in diameter on that day. Of the 147 ran-
domized patients, 34 (23.1%) met these two criteria. Within
the treatment groups, the proportion of patients meeting these
criteria ranged from 13.3% in the placebo group to 32.1% in
the 30mg rLH group (Table II). After controlling for BMI
and the dose of FSH, pairwise comparison of the 30mg rLH
group versus placebo showed a significant difference
(P ¼ 0.048).
Table II shows the secondary efficacy endpoints for the 94
patients who received hCG according to the protocol criteria
(maximum of two follicles with a mean diameter $16 mm).
The proportion of these patients was slightly higher in the
30mg rLH-treated group than in the 60mg rLH-treated
group. The number of follicles $16 mm in diameter on the
day of hCG ranged from one to two with 1.6 ^ 0.5 follicles
in all the rLH groups and 1.8 ^ 0.4 follicles in the placebo
group. This difference did not achieve significance. Further-
more, the number of small follicles (4–10 mm) was not sig-
nificantly different between treatment groups.
If we consider the hormonal parameters at the time of
hCG administration (Table III), the statistical analysis
showed no significant difference for E2 values but signifi-
cantly higher mean levels for LH in the 60mg rLH group
compared with placebo (P ¼ 0.007). Inhibin A and B mean
values on the day of hCG administration were not signifi-
cantly different between groups. However, significant differ-
ences in inhibin B were detected 2 days before hCG
administration, due to a high inhibin B level in the
placebo group (1223.3 ^ 1185.5 pg/ml, compared with
537.3 ^ 460.1 pg/ml in the 6.8mg group (P ¼ 0.013 versus
placebo), 557.5 ^ 459.8 pg/ml in the 30mg group
(P ¼ 0.031) and 500.0 ^ 561.5 pg/ml in the 60mg group
(P ¼ 0.012).
A treatment effect for progesterone values was detected,
due to high mean levels in the 60mg rLH group, and the
difference was highly significant (P , 0.001 at S4). Among
the 94 patients who received hCG, 74 (79%) had a luteal
phase progesterone level $25 nmol/l and the proportion of
patients did not differ significantly between treatment groups.
The pregnancy rate was evaluated in the overall popu-
lation. Twenty-seven of the 147 (18.4%) patients had at least
one serum hCG .10 IU/l. Within treatment groups, the pro-
portion of patients ranged from 10.3% in the 60mg rLH
group to 28.6% in the 30mg rLH group, while being 20% in
the placebo group, 18.8% in the 6.8mg rLH group and 14.3%
in the 13.6mg rLH group. The difference between treatment
Table II. Efficacy results
Placebo 6.8mg rLH 13.6mg rLH 30mg rLH 60mg rLH Total
Duration of FSH treatment (days)
prior to randomisation
9.0 (5.1) 9.1 (3.7) 9.0 (4.3) 11.1 (6.2) 10.6 (5.1) 9.7 (5.0)
FSH dose (IU) prior to randomisation 889.7 (558.6) 870.7 (409.9) 931.3 (522.2) 1099.6 (708.1) 1149.1 (646.4) 984.6 (578.0)
Randomized patients (n) 30 32 28 28 29 147
Patients receiving hCG (%) 17 (56.7) 22 (68.8) 18 (64.3) 21 (75.0) 16 (55.2) 94 (63.9)
Patients with only one follicle $16 (%) 4 (13.3) 8 (25.0) 7 (25.0) 9 (32.1)a 6 (20.7) 34 (23.1)
No. of follicles (day of hCG) (SD)
$ 16 mm 1.8 (0.4) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5)
11–15 mm 3.4 (3.4) 2.9 (1.8) 3.7 (3.5) 3.9 (2.7) 3.2 (3.8) 3.4 (3)
4–10 mm 12 (9.8) 11.8 (6.4) 15.8 (10.4) 12.1 (10.8) 13.9 (10.4) 13 (9.5)
Clinical pregnancy (%) 5 (16.7) 5 (15.6) 3 (10.7) 8 (28.6) 2 (6.9) 23 (15.6)
OHSS (%) 0 2 (6.3) 1 (3.4) 1 (3.3) 1 (3.2) 5 (3.3)
Values are mean (% or SD).
aP , 0.05.
hCG ¼ human chorionic gonadotrophin; rLH ¼ recombinant human LH.
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groups was not significant. Among the 23 clinically pregnant
patients, 17 (73.9%) had exactly one fetal sac seen on ultra-
sound scan, while five (21.7%) had two fetal sacs, and one
(4.3%) had three fetal sacs. Distribution of patients according
to the number of sacs was balanced across treatment groups.
Although the proportion of patients who had two fetal sacs
was higher in the 30mg rLH group, the statistical analysis
did not show any particular dose relationship. Of the 23
patients who had a clinical pregnancy, one had both an
intrauterine and extrauterine pregnancy. This was surgically
treated. Another patient had a miscarriage after visualization
of a fetal sac.
Safety evaluation
All 153 patients who received treatment were included in the
safety analysis.
Local tolerability reactions were reported for 26 (17.0%)
patients. Swelling and bruising were the most frequent types
of reactions. Five (3.3%) patients had OHSS: two in the
6.8mg rLH group and one each in the 13.6, 30 and 60mg
rLH groups. Four OHSS events were of mild severity and
one was graded as a severe event. Overall, there was no
statistically significant difference in OHSS between LH-
supplemented patients (5/117 or 4.3%) versus those women
receiving placebo (0/30) (P ¼ 0.6, Fisher’s exact test). The
proportion of patients who had adverse events was balanced
between groups, as well as distribution of severity and
relationship with study drug. No patients had clinically
abnormal values for any of the haematology and biochemis-
try parameters on days 6–8 post-hCG. Analyses of anti-rLH
antibodies were negative for the overall population.
Discussion
Ovarian stimulation for chronic anovulation is a challenge
for clinicians due to the high risk of over-response, multiple
pregnancy and OHSS. There is still a need for a better
understanding of the control of follicular growth and for
developing new protocols for clinical use. This multicentre,
dose-finding study shows that, in patients over-responding to
FSH during ovulation induction, doses of up to 30mg
rLH/day are well tolerated in the late follicular phase and
appear to increase the proportion of patients developing a
single dominant follicle without inducing any premature
luteinization. These data provide new evidence that, in clini-
cal practice, high-dose LH supplementation in the late fol-
licular phase may be beneficial to reduce the size of the
developing follicular cohort, consistent with the LH ceiling
hypothesis. The clinical relevance of this observation should
be stressed considering that, even with careful stepwise
administration of FSH, the rate of mono-ovulation is only
,65% in stimulated cycles (White et al., 1996; Homburg
and Howles, 1999). Therefore, the safety of step-up protocols
has still to be improved.
Our data extend the ‘LH ceiling’ concept to clinical prac-
tice and confirm the results of a recently published pilot
study (Loumaye et al., 2003). In that study, WHO group II
anovulatory patients were given placebo, or 225 or 450 IU
rLH, without addition of any FSH support, if they presented
an over-response to FSH, defined by the presence of four or
more follicles that were $8 and ,13 mm in diameter. Fol-
licular growth arrest was only observed in patients treated
with rLH (5/12), as attested by a reduction in the adjusted
mean number of follicles $14 mm in diameter. Moreover,
while placebo treatment was not associated with significant
changes in serum E2 levels, administration of rLH alone led
to a further increase in serum E2 levels, as previously
described by Sullivan et al. (1999). However, some patients
with follicle regression presented a sharp decline in serum E2
levels, which could be related to the absence of FSH support
during the late follicular phase.
Our study was set up to establish the minimal effective
dose required to induce atresia of secondary follicles, whilst
supporting the growth of a dominant follicle to pre-ovulatory
conditions. To facilitate this, a low dose of FSH was added
to the rLH/placebo treatment. According to our data, 30mg
rLH seems to be the most appropriate dose to reduce the size
of the developing cohort. Indeed, the proportion of patients
who received hCG and who had exactly one follicle
$16 mm in diameter was significantly higher among patients
treated with 30mg rLH compared with the placebo group. No
statistically significant dose effects were detected for these
secondary outcome measures, possibly because of the rela-
tively small number of patients in each group. Even if we
cannot exclude the possibility that the reduction in the FSH
dose may have contributed to follicular atresia, it seems to be
unlikely due to the pharmacokinetic and pharmacodynamic
properties of FSH preparations (Le Cotonnec et al., 1994).
Therefore, our data suggest that 30mg rLH is the minimal
effective dose required to induce arrest of large follicle
development.
Another report on the consequences of LH activity on the
dynamics of folliculogenesis has been previously reported
by Filicori et al. (2002). In that study, administration of
Table III. Hormone concentrations on the day of hCG administration
Placebo 6.8mg rLH 13.6mg rLH 30mg rLH 60mg rLH Overall
n 17 22 18 21 16 94
E2 (pmol/l) 1692 (1440) 1431 (877) 1698 (1682) 1881 (1897) 1515 (1347) 1642 (1453)
LH (IU/l) 10.3 (11.6) 8.4 (8.3) 6.9 (3.9) 8.3 (3.7) 14.1 (7.6) 9.4 (7.7)
Inhibin A (pg/ml) 74.8 (73.0) 53.8 (41.9) 79.9 (72.3) 80.6 (63.6) 60.5 (65.8) 69.5 (62.5)
Inhibin B (pg/ml) 574 (797) 338 (247) 458.8 (493.8) 547 (708) 462 (1030) 472 (672)
Values are mean (SD).
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increasing doses of hCG (from 50 to 200 IU) from the mid-
follicular phase can significantly reduce the number of small
follicles without any change in the number of large follicles.
However, many discrepancies exist on the design of these
experiments and may explain the opposite conclusion. First,
the difference in the pharmacokinetic properties of the drugs
used may account for the divergent effects. Indeed, the half-
life of hCG is much longer than that of LH (,36 versus
11 h) (Trinchard-Lugan et al., 2002). Second, the design of
the study performed by Filicori et al. differed from our own
because a hypogonadotrophic state was induced prior to ova-
rian stimulation through a GnRH agonist administration.
Therefore, the considerable difference in endogenous LH
secretion resulting from these two protocols means that the
effectiveness of exogenous LH supplementation cannot be
strictly compared. Most importantly, in Filicori et al.’s study,
administration of hCG preparations was started on a fixed
day (day 7) of the ovarian stimulation, without any criteria of
follicular growth. As LH receptors only appear on differen-
tiated granulosa cells (Richards et al., 1987), it is uncertain
whether the effects of hCG preparations on follicular growth
were actually related to a direct LH effect on granulosa cells.
The purpose of our study was to address the issue of the
direct effects of LH on follicular growth. Therefore, rLH was
administered when follicles reached 11–15 mm in diameter
(i.e. when LH receptors are constantly expressed on differen-
tiated granulosa cells) (Richards et al., 1987). However,
while this design allowed us to more specifically assess the
direct effect of LH supplementation on follicular growth, we
cannot exclude that the parallel stimulatory effect of LH on
androgen secretion may also interfere with the control of
follicular growth.
Another interesting finding from our study concerns the
dose-related effect of LH on the luteinization process of
granulosa cells. Our data clearly indicate that administration
of rLH at a daily dose up to 30mg does not induce premature
luteinization. In contrast, a dose of 60mg rLH was consist-
ently associated with an increase in progesterone values.
These findings provide evidence for a pivotal role of LH in
the process of luteinization, and for an LH ceiling effect at
.30mg daily dose.
While other studies reported a relationship between the
administered dose of FSH and follicular phase progesterone
values (Ubaldi et al., 1996; Filicori et al., 2002), our results
strongly suggest that LH plays a key role in this process.
They also show that the dual effects of LH on the luteiniza-
tion process and on the control of follicular growth are not
equivalent, as the dose required to exert control upon follicu-
lar growth is slightly lower than that effective to induce lutei-
nization. Our results contrast with the data provided by
Filicori et al. (2002), who reported a slight but significant
increase of progesterone values in the whole group of
patients treated with hCG and did not observe any dose-
dependent effect of hCG preparations. This discrepancy may
be related to the different pharmacokinetic properties of both
preparations. They also emphasize that conclusions drawn
from studies using hCG preparations cannot be applied to
those performed with rLH.
Finally, our study shows that, while the clinical pregnancy
rate was slightly higher in patients treated with 30mg rLH,
the increase in progesterone secretion induced by a dose of
60mg rLH may have accounted for the reduction in the preg-
nancy rate of that group. No clear benefit was observed on
the risk of multiple pregnancy rate. This may be related to
the small number of patients in each treatment group and
further studies are required to investigate whether addition of
LH bioactivity is actually effective to prevent the risk of
multiple pregnancy.
In summary, this randomized, placebo-contolled, dose-
finding study shows that, in patients over-responding to FSH
during ovulation induction, doses of rLH up to 30mg/day are
well tolerated in the late follicular phase and appear to
increase the proportion of patients developing a single domi-
nant follicle. Our data support the ‘LH ceiling’ concept,
whereby addition of a high dose of LH is able to control
follicular growth by inducing atresia of developing follicles.
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